publication date: Dec. 22, 2016
CCL Dec 2016 - Dec. 22, 2016
13651

December 2016 PDF

  Lung Cancer Tagrisso Shows Superiority vs. Chemo in EGFR T790M Mutation-Positive Disease

Data from phase III trial showed that Tagrisso (osimertinib) second-line therapy improved progression-free survival by 5.7 months, compared with standard platinum-based doublet chemotherapy (Hazard Ratio [HR]=0.3).

Zykadia Shows 16.6-month PFS in First-Line Patients with ALK+ NSCLC Nintedanib Meets PFS Endpoint in Phase II Mesothelioma Trial   Breast Cancer Lilly Presents Phase II Data on Abemaciclib in Early Breast Cancer

A phase II study of abemaciclib, a cyclin-dependent kinase 4 and CDK 6 inhibitor, met its primary endpoint of reducing expression of Ki67, a biomarker of cell proliferation, after two weeks of treatment.

Presentations at San Antonio Symposium Focus on Oncotype DX in Tailoring Treatment Study Suggests that BCI May Help Identify T1N0 Patients for Extended Endocrine Therapy Study Shows Targeted Therapy Needed for Breast Cancer with Brain Metastases Large Study Finds No Evidence for Age-Based Mammography Cut-Off Hair Loss Prevention Found Safe, Effective in Prospective, Multicenter Randomized Trial   Hematologic … Continue reading CCL Dec 2016

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.